Ligand Pharmaceuticals (LGND) Receivables (2010 - 2026)

Ligand Pharmaceuticals has disclosed Receivables across 17 years of filings, most recently posting $53.4 million for Q1 2026.

• Receivables for Q1 2026 came in at $53.4 million, up 38.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.4 million (up 38.69% YoY), and the FY2025 annual result was $59.6 million, up 55.31% from the prior year.
• Receivables came in at $53.4 million for Q1 2026 at Ligand Pharmaceuticals, down from $59.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $65.2 million in Q3 2022 to a low of $28.0 million in Q2 2023.
• The 5-year median for Receivables is $38.4 million (2024), against an average of $42.0 million.
• Across the five-year window, Receivables tumbled 64.4% in 2022 and jumped 67.73% in 2025, its largest moves.
• Ligand Pharmaceuticals' Receivables stood at $30.4 million in 2022, then grew by 8.19% to $32.9 million in 2023, then gained by 16.58% to $38.4 million in 2024, then jumped by 55.31% to $59.6 million in 2025, then declined by 10.43% to $53.4 million in 2026.
• The last three Receivables figures came in at $53.4 million (Q1 2026), $59.6 million (Q4 2025), and $57.6 million (Q3 2025), per Business Quant data.